Stroke in patients with sickle cell disease

Expert Review of Hematology

Volumn 6, Issue 3, 2013, Pages 301-316

  Webb, Jennifer ^a,b   Kwiatkowski, Janet L ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cerebrovascular accident; chronic transfusion therapy; review; sickle cell anemia; stroke

Indexed keywords

FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; NITRIC OXIDE; THROMBIN;

ATAXIA; BLOOD FLOW VELOCITY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHILDHOOD DISEASE; COGNITION; CORD BLOOD STEM CELL TRANSPLANTATION; ERYTHROCYTE ADHESIVENESS; ERYTHROCYTE TRANSFUSION; EXECUTIVE FUNCTION; HAPLOTYPE; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMAGE RECONSTRUCTION; INTRAVASCULAR HEMOLYSIS; MOYAMOYA DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN CONSUMPTION; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SICKLE CELL ANEMIA; SILENT MYOCARDIAL INFARCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VERTIGO; VOMITING; VON WILLEBRAND DISEASE; WORKING MEMORY;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BLOOD VESSELS; BRAIN; CEREBRAL INFARCTION; HUMANS; HYDROXYUREA; MAGNETIC RESONANCE IMAGING; RISK FACTORS; STROKE; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 84879363753     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.13.25     Document Type: Review

References (167)

1. Ohene-Frempong K, Weiner SJ, Sleeper LA et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 91(1), 288-294 (1998).
2. Pegelow CH, Macklin EA, Moser FG et al. Longitudinal changes in brain magnetic resonance imaging fndings in children with sickle cell disease. Blood 99(8), 3014-3018 (2002).
3. Bernaudin F, Verlhac S, Arnaud C et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood 117 (4), 1130-1140 ; qu i z 1436 (2011).
4. Casella JF, King AA, Barton B et al. Design of the silent cerebral infarct transfusion (SIT) trial. Pediatr. Hematol. Oncol. 27(2), 69-89 (2010).
5. Wang WC, Pavlakis SG, Helton KJ et al.; BABY HUG Investigators. MRI abnormalities of the brain in one-year-old children with sickle cell anemia. Pediatr. Blood Cancer 51(5), 643-646 (2008).
6. Kwiatkowski JL, Zimmerman RA, Pollock AN et al. Silent infarcts in young children with sickle cell disease. Br. J. Haematol. 146(3), 300-305 (2009).
7. Bernaudin F, Verlhac S, Fréard F et al. Multicenter prospective study of children with sickle cell disease: radiographic and psychometric correlation. J. Child Neurol. 15(5), 333-343 (2000).
8. Armstrong FD, Thompson RJ Jr, Wang W et al.; Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease. Pediatrics 97(6 Pt 1), 864-870 (1996).
9. Schatz J, Brown RT, Pascual JM, Hsu L, DeBaun MR. Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology 56(8), 1109-1111 (2001).
10. Schatz J, Buzan R. Decreased corpus callosum size in sickle cell disease: relationship with cerebral infarcts and cognitive functioning. J. Int. Neuropsychol. Soc. 12(1), 24-33 (2006).
11. Schatz J, Finke RL, Kellett JM, Kramer JH. Cognitive functioning in children with sickle cell disease: a meta-analysis. J. Pediatr. Psychol. 27(8), 739-748 (2002).
12. Schatz J, White DA, Moinuddin A, Armstrong M, DeBaun MR. Lesion burden and cognitive morbidity in children with sickle cell disease. J. Child Neurol. 17(12), 891-895 (2002).
13. Brown RT, Davis PC, Lambert R, Hsu L, Hopkins K, Eckman J. Neurocognitive functioning and magnetic resonance imaging in children with sickle cell disease. J. Pediatr. Psychol. 25(7), 503-513 (2000).
14. Vichinsky EP, Neumayr LD, Gold JI et al.; Neuropsychological Dysfunction and Neuroimaging Adult Sickle Cell Anemia Study Group. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA 303(18), 1823-1831 (2010).
15. Kugler S, Anderson B, Cross D et al. Abnormal cranial magnetic resonance imaging scans in sickle-cell disease. Neurological correlates and clinical implications. Arch. Neurol. 50(6), 629-635 (1993).
16. DeBaun MR, Armstrong FD, McKinstry RC, Ware RE, Vichinsky E, Kirkham FJ. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood 119(20), 4587-4596 (2012).
17. Adams RJ, Nichols FT 3rd, Aaslid R et al. Cerebral vessel stenosis in sickle cell disease: criteria for detection by transcra-nial Doppler. Am. J. Pediatr. Hematol. Oncol. 12(3), 277-282 (1990).
18. Platt OS. Preventing stroke in sickle cell anemia. N. Engl. J. Med. 353(26), 2743-2745 (2005).
19. Frenette PS. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr. Opin. Hematol. 9(2), 101-106 (2002).
20. Joneckis CC, Ackley RL, Orringer EP, Wayner EA, Parise LV. Integrin alpha 4 beta 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood 82(12), 3548-3555 (1993).
21. Swerlick RA, Eckman JR, Kumar A, Jeitler M, Wick TM. Alpha 4 beta 1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium. Blood 82(6), 1891-1899 (1993).
22. Natarajan M, Udden MM, McIntire LV. Adhesion of sickle red blood cells and damage to interleukin-1 beta stimulated endothelial cells under fow in vitro. Blood 87(11), 4845-4852 (1996).
23. Embury SH, Matsui NM, Ramanujam S et al. The contribution of endothelial cell P-selectin to the microvascular fow of mouse sickle erythrocytes in vivo. Blood 104(10), 3378-3385 (2004).
24. Hillery CA, Scott JP, Du MC. The carboxy-terminal cell-binding domain of thrombospondin is essential for sickle red blood cell adhesion. Blood 94(1), 302-309 (1999).
25. Gee BE, Platt OS. Sickle reticulocytes adhere to VCAM-1. Blood 85(1), 268-274 (1995).
26. Kaul DK, Nagel RL, Chen D, Tsai HM. Sickle erythrocyte-endothelial interactions in microcirculation: the role of von Willebrand factor and implications for vasoocclusion. Blood 81(9), 2429-2438 (1993).
27. Wautier JL, Pintigny D, Wautier MP et al. Fibrinogen, a modulator of erythrocyte adhesion to vascular endothelium. J. Lab. Clin. Med. 101(6), 911-920 (1983).
28. Ataga KI, Moore CG, Hillery CA et al. Coagulation activation and infammation in sickle cell disease-associated pulmonary hypertension. Haematologica 93(1), 20-26 (2008).
29. Okpala I. Leukocyte adhesion and the pathophysiology of sickle cell disease. Curr. Opin. Hematol. 13(1), 40-44 (2006).
30. Frenette PS. Sickle cell vasoocclusion: heterotypic, multicellular aggregations driven by leukocyte adhesion. Microcirculation 11(2), 167-177 (2004).
31. Morris CR, Kato GJ, Poljakovic M et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 294(1), 81-90 (2005).
32. Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am. Soc. Hematol. Educ. Program 177-185 (2008).
33. Morris CR, Suh JH, Hagar W et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood 111(1), 402-410 (2008).
34. Lezcano NE, Odo N, Kutlar A, Brambilla D, Adams RJ. Regular transfusion lowers plasma free hemoglobin in children with sickle-cell disease at risk for stroke. Stroke. 37(6), 1424-1426 (2006).
35. Adams RJ, Kutlar A, McKie V et al. Alpha thalassemia and stroke risk in sickle cell anemia. Am. J. Hematol. 45(4), 279-282 (1994).
36. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 21(1), 37-47 (2007).
37. O'Driscoll S, Height SE, Dick MC, Rees DC. Serum lactate dehydrogenase activity as a biomarker in children with sickle cell disease. Br. J. Haematol. 140(2), 206-209 (2008).
38. Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am. J. Med. 65 (3), 461-471 (1978).
39. Brandão RA, de Carvalho GT, Reis BL, Bahia E, de Souza AA. Intracranial aneurysms in sickle cell patients: report of 2 cases and review of the literature. Surg. Neurol. 72(3), 296-299; discussion 299 (2009).
40. Moritani T, Numaguchi Y, Lemer NB et al. Sickle cell cerebrovascular disease: usual and unusual fndings on MR imaging and MR angiography. Clin. Imaging 28(3), 173-186 (2004).
41. Dobson SR, Holden KR, Nietert PJ et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood 99(9), 3144-3150 (2002).
42. Pegelow CH, Wang W, Granger S et al.; STOP Trial. Silent infarcts in children with sickle cell anemia and abnormal cerebral artery velocity. Arch. Neurol. 58(12), 2017-2021 (2001).
43. Waterston JA, Brown MM, Butler P, Swash M. Small deep cerebral infarcts associated with occlusive internal carotid artery disease. A hemodynamic phenomenon? Arch. Neurol. 47(9), 953-957 (1990).
44. Dowling MM, Quinn CT, Rogers ZR, Buchanan GR. Acute silent cerebral infarction in children with sickle cell anemia. Pediatr. Blood Cancer 54(3), 461-464 (2010).
45. Wang WC, Gallagher DM, Pegelow CH et al. Multicenter comparison of magnetic resonance imaging and transcranial Doppler ultrasonography in the evaluation of the central nervous system in children with sickle cell disease. J. Pediatr. Hematol. Oncol. 22(4), 335-339 (2000).
46. Hulbert ML, McKinstry RC, Lacey JL et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after frst strokes in children with sickle cell disease. Blood 117 (3), 772-779 (2011).
47. Miller ST, Macklin EA, Pegelow CH et al.; Cooperative Study of Sickle Cell Disease. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J. Pediatr. 139(3), 385-390 (2001).
48. Kirkham FJ, Hewes DK, Prengler M, Wade A, Lane R, Evans JP. Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease. Lancet 357(9269), 1656-1659 (2001).
49. Goldstein NA, Keller R, Rey K et al. Sleep-disordered breathing and transcranial Dopplers in sickle cell disease. Arch. Otolaryngol. Head Neck Surg. 137(12), 1263-1268 (2011).
50. Tripathi A, Jerrell JM, Stallworth JR. Cost-effectiveness of adenotonsillectomy in reducing obstructive sleep apnea, cerebrovascular ischemia, vaso-occlusive pain, and ACS episodes in pediatric sickle cell disease. Ann. Hematol. 90(2), 145-150 (2011).
51. Bulas DI, Jones A, Seibert JJ, Driscoll C, O'Donnell R, Adams RJ. Transcranial Doppler (TCD) screening for stroke prevention in sickle cell anemia: pitfalls in technique variation. Pediatr. Radiol. 30(11), 733-738 (2000).
52. Adams RJ, Nichols F T, Figueroa R, McKie V, Lott T. Transcranial Doppler correlation with cerebral angiography in sickle cell disease. Stroke. 23 (8), 1073-1077 (1992).
53. Adams RJ, McKie VC, Carl EM et al. Long-term stroke risk in children with sickle cell disease screened with transcra-nial Doppler. Ann. Neurol. 42(5), 699-704 (1997).
54. Abboud MR, Cure J, Granger S et al.; STOP study. Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography fndings enrolled in the STOP study. Blood 103(7), 2822-2826 (2004).
55. Gorman MJ, Nyström K, Carbonella J, Pearson H. Submandibular TCD approach detects post-bulb ICA stenosis in children with sickle cell anemia. Neurology 73(5), 362-365 (2009).
56. Deane CR, Goss D, Bartram J et al. Extracranial internal carotid arterial disease in children with sickle cell anemia. Haematologica 95(8), 1287-1292 (2010).
57. Deane CR, Goss D, O'Driscoll S et al. Transcranial Doppler scanning and the assessment of stroke risk in children with HbSC [corrected] disease. Arch. Dis. Child. 93(2), 138-141 (2008).
58. Valadi N, Silva GS, Bowman LS et al. Transcranial Doppler ultrasonography in adults with sickle cell disease. Neurology 67(4), 572-574 (2006).
59. Sampaio Silva G, Vicari P, Figueiredo MS, Filho AC, Valadi N, Massaro AR. Transcranial Doppler in adult patients with sickle cell disease. Cerebrovasc. Dis. 21(1-2), 38-41 (2006).
60. Silva GS, Vicari P, Figueiredo MS, Carrete H Jr, Idagawa MH, Massaro AR. Brain magnetic resonance imaging abnormalities in adult patients with sickle cell disease: correlation with transcranial Doppler fndings. Stroke 40(7), 2408-2412 (2009).
61. Strouse JJ, Hulbert ML, DeBaun MR, Jordan LC, Casella JF. Primary hemor-rhagic stroke in children with sickle cell disease is associated with recent transfusion and use of corticosteroids. Pediatrics 118 (5), 1916-1924 (2006).
62. Kinney TR, Sleeper LA, Wang WC et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics 103(3), 640-645 (1999).
63. DeBaun MR, Sarnaik SA, Rodeghier MJ et al. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood 119 (16), 3684-3690 (2012).
64. Thangarajh M, Yang G, Fuchs D et al. Magnetic resonance angiography-defned intracranial vasculopathy is associated with silent cerebral infarcts and glucose-6-phos-phate dehydrogenase mutation in children with sickle cell anaemia. Br. J. Haematol. 159 (3), 352-359 (2012).
65. Bernaudin F, Verlhac S, Chevret S et al. G6PD defciency, absence of alpha-thalas-semia, and hemolytic rate at baseline are signifcant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia. Blood 112(10), 4314-4317 (2008).
66. Rees DC, Lambert C, Cooper E et al. Glucose 6 phosphate dehydrogenase defciency is not associated with cerebrovas-cular disease in children with sickle cell anemia. Blood 114(3), 742-743; author reply 743 (2009).
67. Miller ST, Milton J, Steinberg MH. G6PD defciency and stroke in the CSSCD. Am. J. Hematol. 86(3), 331 (2011).
68. Hsu LL, Miller ST, Wright E et al.; Stroke Prevention Trial (STOP) and the Cooperative Study of Sickle Cell Disease (CSSCD). Alpha thalassemia is associated with decreased risk of abnormal transcra-nial Doppler ultrasonography in children with sickle cell anemia. J. Pediatr. Hematol. Oncol. 25(8), 622-628 (2003).
69. Gill FM, Sleeper LA, Weiner SJ et al. Clinical events in the frst decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 86(2), 776-783 (1995).
70. Kwiatkowski JL, Hunter J V, Smith-Whit-ley K, Katz ML, Shults J, Ohene-Frempong K. Transcranial Doppler ultrasonography in siblings with sickle cell disease. Br. J. Haematol. 121(6), 932-937 (2003).
71. Driscoll MC, Hurlet A, Styles L et al. Stroke risk in siblings with sickle cell anemia. Blood 101(6), 2401-2404 (2003).
72. Hoppe C, Klitz W, Cheng S et al.; CSSCD Investigators. Gene interactions and stroke risk in children with sickle cell anemia. Blood 103(6), 2391-2396 (2004).
73. Hoppe C, Klitz W, D'Harlingue K et al.; Stroke Prevention Trial in Sickle Cell Anemia (STOP) Investigators. Confrma-tion of an association between the TNF(-308) promoter polymorphism and stroke risk in children with sickle cell anemia. Stroke 38(8), 2241-2246 (2007).
74. Styles LA, Hoppe C, Klitz W, Vichinsky E, Lubin B, Trachtenberg E. Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. Blood 95(11), 3562-3567 (2000).
75. Hoppe C, Klitz W, Noble J, Vigil L, Vichinsky E, Styles L. Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood 101(7), 2865-2869 (2003).
76. Taylor JG 6th, Tang DC, Savage SA et al. Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood 100(13), 4303-4309 2002).
77. Flanagan JM, Frohlich DM, Howard TA et al. Genetic predictors for stroke in children with sickle cell anemia. Blood 117(24), 6681-6684 (2011).
78. Adams GT, Snieder H, McKie VC et al. Genetic risk factors for cerebrovascular disease in children with sickle cell disease: design of a case-control association study and genomewide screen. BMC Med. Genet. 4, 6 (2003).
79. Ohene-Frempong K. Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations. Semin. Hematol. 28(3), 213-219 (1991).
80. Hulbert ML, Scothorn DJ, Panepinto JA et al. Exchange blood transfusion compared with simple transfusion for frst overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia. J. Pediatr. 149(5), 710-712 (2006).
81. Hariman LM, Griffth ER, Hurtig AL, Keehn MT. Functional outcomes of children with sickle-cell disease affected by stroke. Arch. Phys. Med. Rehabil. 72(7), 498-502 (1991).
82. King AA, DeBaun MR, White DA. Need for cognitive rehabilitation for children with sickle cell disease and strokes. Expert Rev. Neurother. 8(2), 291-296 (2008).
83. King AA, White DA, McKinstry RC, Noetzel M, Debaun MR. A pilot randomized education rehabilitation trial is feasible in sickle cell and strokes. Neurology 68(23), 2008-2011 (2007).
84. Steen RG, Reddick WE, Mulhern RK et al. Quantitative MRI of the brain in children with sickle cell disease reveals abnormalities unseen by conventional MRI. J. Magn. Reson. Imaging 8(3), 535-543 (1998).
85. McQuaker IG, Jaspan T, McConachie NS, Dolan G. Coil embolization of cerebral aneurysms in patients with sickling disorders. Br. J. Haematol. 106 (2), 388-390 (1999).
86. Kirkham FJ, DeBaun MR. Stroke in children with sickle cell disease. Curr. Treat. Options Neurol. 6(5), 357-375 (2004).
87. Sarnaik S, Soorya D, Kim J, Ravin-dranath Y, Lusher J. Periodic transfusions for sickle cell anemia and CNS infarction. Am. J. Dis. Child. 133(12), 1254-1257 (1979).
88. Scothorn DJ, Price C, Schwartz D et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least fve years after initial stroke. J. Pediatr. 140 (3), 348-354 (2002).
89. Pegelow CH, Adams RJ, McKie V et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J. Pediatr. 126(6), 896-899 (1995).
90. Kwiatkowski JL, Yim E, Miller S, Adams RJ; STOP 2 Study Investigators. Effect of transfusion therapy on transcranial Doppler ultrasonography velocities in children with sickle cell disease. Pediatr. Blood Cancer 56(5), 777-782 (2011).
91. Bishop S, Matheus MG, Abboud MR et al. Effect of chronic transfusion therapy on progression of neurovascular pathology in pediatric patients with sickle cell anemia. Blood Cells Mol. Dis. 47(2), 125-128 (2011).
92. Brousse V, Hertz-Pannier L, Consigny Y et al. Does regular blood transfusion prevent progression of cerebrovascular lesions in children with sickle cell disease? Ann. Hematol. 88(8), 785-788 (2009).
93. Bader-Meunier B, Verlhac S, Elmaleh-Bergès M et al. Effect of transfusion therapy on cerebral vasculopathy in children with sickle-cell anemia. Haematologica 94(1), 123-126 (2009).
94. Wang WC, Kovnar EH, Tonkin IL et al. High risk of recurrent stroke after discontinuance of fve to twelve years of transfusion therapy in patients with sickle cell disease. J. Pediatr. 118(3), 377-382 (1991).
95. Venkateswaran L, Teruya J, Bustillos C, Mahoney D Jr, Mueller BU. Red cell exchange does not appear to increase the rate of allo-and auto-immunization in chronically transfused children with sickle cell disease. Pediatr. Blood Cancer 57(2), 294-296 (2011).
96. Vichinsky EP. Current issues with blood transfusions in sickle cell disease. Semin. Hematol. 38(1 Suppl. 1), 14-22 (2001).
97. Fung EB, Harmatz P, Milet M et al.; Multi-Center Study of Iron Overload Research Group. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload. Am. J. Hematol. 82(4), 255-265 (2007).
98. Kim HC, Dugan NP, Silber JH et al. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood 83(4), 1136-1142 (1994).
99. Adams DM, Schultz WH, Ware RE, Kinney TR. Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients. J. Pediatr. Hematol. Oncol. 18(1), 46-50 (1996).
100. Hilliard LM, Williams BF, Lounsbury AE, Howard TH. Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients. Am. J. Hematol. 59(1), 28-35 (1998).
101. Singer ST, Quirolo K, Nishi K, Hackney-Stephens E, Evans C, Vichinsky EP. Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J. Clin. Apher. 14(3), 122-125 (1999).
102. Cohen AR, Martin MB, Silber JH, Kim HC, Ohene-Frempong K, Schwartz E. A modifed transfusion program for prevention of stroke in sickle cell disease. Blood 79 (7), 1657-1661 (1992).
103. Miller ST, Jensen D, Rao SP. Less intensive long-term transfusion therapy for sickle cell anemia and cerebrovascular accident. J. Pediatr. 120(1), 54-57 (1992).
104. Ali SB, Moosang M, King L, Knight-Mad den J, Reid M. Stroke recurrence in children with sickle cell disease treated with hydroxyurea following frst clinical stroke. Am. J. Hematol. 86(10), 846-850 (2011).
105. Ware RE, Zimmerman SA, Sylvestre PB et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J. Pediatr. 145(3), 346-352 (2004).
106. Ware RE, Helms RW; SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood 119(17), 3925-3932 (2012).
107. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 94(9), 3022-3026 (1999).
108. Sumoza A, de Bisotti R, Sumoza D, Fairbanks V. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am. J. Hematol. 71(3), 161-165 (2002).
109. Lefèvre N, Dufour D, Gulbis B, Lê PQ, Heijmans C, Ferster A. Use of hydroxyurea in prevention of stroke in children with sickle cell disease. Blood 111 (2), 963-964 ; author reply 964 (2008).
110. Fryer RH, Anderson RC, Chiriboga CA, Feldstein NA. Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure. Pediatr. Neurol. 29(2), 124-130 (2003).
111. Vernet O, Montes JL, O'Gorman AM, Baruchel S, Farmer JP. Encephaloduroarte-rio-synangiosis in a child with sickle cell anemia and moyamoya disease. Pediatr. Neurol. 14(3), 226-230 (1996).
112. Abboud MR, Yim E, Musallam KM, Adams RJ; STOP II Study Investigators. Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. Blood 118(4), 894-898 (2011).
113. Walters MC, Patience M, Leisenring W et al.; Multicenter Investigation of Bone Marrow Transplantation for Sickle Cell Disease. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol. Blood Marrow Transplant. 7(12), 665-673 (2001).
114. Panepinto JA, Walters MC, Carreras J et al.; Non-Malignant Marrow Disorders Working Committee, Center for International Blood and Marrow Transplant Research. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br. J. Haematol. 137(5), 479-485 (2007).
115. Walters MC, Sullivan KM, Bernaudin F et al. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood 85(4), 879-884 (1995).
116. Walters MC, Hardy K, Edwards S et al.; Multicenter Study of Bone Marrow Transplantation for Sickle Cell Disease. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol. Blood Marrow Transplant. 16(2), 263-272 (2010).
117. Bernaudin F, Socie G, Kuentz M et al.; SFGM-TC. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 110 (7), 2749-2756 (2007).
118. Walters MC, Patience M, Leisenring W et al. Barriers to bone marrow transplanta-tion for sickle cell anemia. Biol. Blood Marrow Transplant. 2 (2), 100-104 (1996).
119. Kodish E, Lantos J, Stocking C, Singer PA, Siegler M, Johnson FL. Bone marrow transplantation for sickle cell disease. A study of parents' decisions. N. Engl. J. Med. 325(19), 1349-1353 (1991).
120. Wu CJ, Gladwin M, Tisdale J et al. Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. Br. J. Haematol. 139(3), 504-507 (2007).
121. Krishnamurti L, Kharbanda S, Biernacki MA et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol. Blood Marrow Transplant. 14(11), 1270-1278 (2008).
122. Horwitz ME, Spasojevic I, Morris A et al. Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics. Biol. Blood Marrow Transplant. 13(12), 1422-1426 (2007).
123. Brichard B, Vermylen C, Ninane J, Cornu G. Persistence of fetal hemoglobin production after successful transplantation of cord blood stem cells in a patient with sickle cell anemia. J. Pediatr. 128(2), 241-243 (1996).
124. Miniero R, Rocha V, Saracco P et al. Cord blood transplantation (CBT) in hemoglo-binopathies. Eurocord. Bone Marrow Transplant. 22(Suppl. 1), S78-S79 (1998).
125. Gore L, Lane PA, Quinones RR, Giller RH. Successful cord blood transplantation for sickle cell anemia from a sibling who is human leukocyte antigen-identical: implications for comprehensive care. J. Pediatr. Hematol. Oncol. 22(5), 437-440 (2000).
126. Locatelli F, Rocha V, Reed W et al.; Eurocord Transplant Group. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 101(6), 2137-2143 (2003).
127. Adamkiewicz TV, Szabolcs P, Haight A et al. Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatr. Transplant. 11(6), 641-644 (2007).
128. Mazur M, Kurtzberg J, Halperin E, Ciocci G, Szabolcs P. Transplantation of a child with sickle cell anemia with an unrelated cord blood unit after reduced intensity conditioning. J. Pediatr. Hematol. Oncol. 28(12), 840-844 (2006).
129. Sauter C, Rausen AR, Barker JN. Successful unrelated donor cord blood transplantation for adult sickle cell disease and Hodgkin lymphoma. Bone Marrow Transplant. 45(7), 1252 (2010).
130. Kamani NR, Walters MC, Carter S et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the Phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol. Blood Marrow Transplant. 18(8), 1265-1272 (2012).
131. Raj A, Bertolone S, Cheerva A. Successful treatment of refractory autoimmune hemolytic anemia with monthly rituximab following nonmyeloablative stem cell transplantation for sickle cell disease. J. Pediatr. Hematol. Oncol. 26 (5), 312-314 (2004).
132. Brodsky RA, Luznik L, Bolaños-Meade J, Leffell MS, Jones RJ, Fuchs EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 42(8), 523-527 (2008).
133. Bolaños-Meade J, Fuchs EJ, Luznik L et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 120(22), 4285-4291 (2012).
134. Machado RF, Martyr S, Kato GJ et al. Sildenafl therapy in patients with sickle cell disease and pulmonary hypertension. Br. J. Haematol. 130(3), 445-453 (2005).
135. Machado RF, Barst RJ, Yovetich NA et al.; Walk-PHaSST Investigators and Patients. Hospitalization for pain in patients with sickle cell disease treated with sildenafl for elevated TRV and low exercise capacity. Blood 118(4), 855-864 (2011).
136. Kaul DK, Zhang X, Dasgupta T, Fabry ME. Arginine therapy of transgenic-knock-out sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 295(1), H39-H47 (2008).
137. Morris CR, Kuypers FA, Larkin S et al. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br. J. Haematol. 111 (2), 498-500 (2000).
138. Kato GJ. Novel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I. Hematology Am. Soc. Hematol. Educ. Program 186-192 (2008).
139. Hoppe C, Kuypers F, Larkin S, Hagar W, Vichinsky E, Styles L. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br. J. Haematol. 153 (5), 655-663 (2011).
140. Ataga KI, Reid M, Ballas SK et al.; ICA-17043-10 Study Investigators. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a Phase III randomized, placebo-controlled, doubleblind study of the Gardos channel blocker senicapoc (ICA-17043). Br. J. Haematol. 153(1), 92-104 (2011).
141. Adams RJ, McKie VC, Hsu L et al. Prevention of a frst stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N. Engl. J. Med. 339(1), 5-11 (1998).
142. Adams RJ, Brambilla DJ, Granger S et al.; STOP Study. Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood 103(10), 3689-3694 (2004).
143. Nichols FT, Jones AM, Adams RJ. Stroke prevention in sickle cell disease (STOP) study guidelines for transcranial Doppler testing. J. Neuroimaging 11(4), 354-362 (2001).
144. Pavlakis SG, Rees RC, Huang X et al.; BABY HUG Investigators. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatr. Blood Cancer 54(2), 256-259 (2010).
145. Wang WC, Ware RE, Miller ST et al.; BABY HUG Investigators. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 377(9778), 1663-1672 (2011).
146. Lebensburger JD, Miller ST, Howard TH et al.; BABY HUG Investigators. Infuence of severity of anemia on clinical fndings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatr. Blood Cancer 59(4), 675-678 (2012).
147. Fullerton HJ, Adams RJ, Zhao S, Johnston SC. Declining stroke rates in Californian children with sickle cell disease. Blood 104(2), 336-339 (2004).
148. McCarville MB, Goodin GS, Fortner G et al. Evaluation of a comprehensive transcranial doppler screening program for children with sickle cell anemia. Pediatr. Blood Cancer 50(4), 818-821 (2008).
149. Enninful-Eghan H, Moore RH, Ichord R, Smith-Whitley K, Kwiatkowski JL. Transcranial Doppler ultrasonography and prophylactic transfusion program is effective in preventing overt stroke in children with sickle cell disease. J. Pediatr. 157(3), 479-484 (2010).
150. McCavit TL, Gilbert M, Buchanan GR. Prophylactic penicillin after 5 years of age in patients with sickle cell disease: A survey of sickle cell disease experts. Pediatr. Blood Cancer 60(6), 935-939 (2012).
151. Krejza J, Mariak Z, Melhem ER, Bert RJ. A guide to the identifcation of major cerebral arteries with transcranial color Doppler sonography. AJR. Am. J. Roentgenol. 174(5), 1297-1303 (2000).
152. Bazzocchi M, Quaia E, Zuiani C, Moroldo M. Transcranial Doppler: state of the art. Eur. J. Radiol. 27(Suppl. 2), S141-S148 (1998).
153. Bulas D. Screening children for sickle cell vasculopathy: guidelines for transcranial Doppler evaluation. Pediatr. Radiol. 35 (3), 235-241 (2005).
154. Neish AS, Blews DE, Simms CA, Merritt RK, Spinks AJ. Screening for stroke in sickle cell anemia: comparison of transcranial Doppler imaging and nonimaging US techniques. Radiology 222(3), 709-714 (2002).
155. Malouf AJ Jr, Hamrick-Turner JE, Doherty MC, Dhillon GS, Iyer RV, Smith MG. Implementation of the STOP protocol for stroke prevention in sickle cell anemia by using duplex power Doppler imaging. Radiology 219 (2), 359-365 (2001).
156. Jones AM, Seibert JJ, Nichols FT et al. Comparison of transcranial color Doppler imaging (TCDI) and transcranial Doppler (TCD) in children with sickle-cell anemia. Pediatr. Radiol. 31(7), 461-469 (2001).
157. Jones A, Granger S, Brambilla D et al. Can peak systolic velocities be used for prediction of stroke in sickle cell anemia? Pediatr. Radiol. 35(1), 66-72 (2005).
158. Zimmerman RA. MRI/MRA evaluation of sickle cell disease of the brain. Pediatr. Radiol. 35(3), 249-257 (2005).
159. Kandeel AY, Zimmerman RA, Ohene-Frempong K. Comparison of magnetic resonance angiography and conventional angiography in sickle cell disease: clinical signifcance and reliability. Neuroradiology 38(5), 409-416 (1996).
160. Al-Kandari FA, Owunwanne A, Syed GM et al. Regional cerebral blood fow in patients with sickle cell disease: study with single photon emission computed tomography. Ann. Nucl. Med. 21(8), 439-445 (2007).
161. Christen T, Bolar DS, Zaharchuk G. Imaging brain oxygenation with MRI using blood oxygenation approaches: methods, validation, and clinical applications. AJNR. Am. J. Neuroradiol. (2012).
162. Adams RJ, Brambilla D; Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N. Engl. J. Med. 353(26), 2769-2778 (2005).
163. Gulbis B, Haberman D, Dufour D et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovas-cular events: the Belgian experience. Blood 105(7), 2685-2690 (2005).
164. Kratovil T, Bulas D, Driscoll MC, Speller-Brown B, McCarter R, Minniti CP. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatr. Blood Cancer 47(7), 894-900 (2006).
165. Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial Doppler fow velocities in children with sickle cell anemia. Blood 110(3), 1043-1047 (2007).
166. Tsaras G, Owusu-Ansah A, Boateng FO, Amoateng-Adjepong Y. Complications associated with sickle cell trait: a brief narrative review. Am. J. Med. 122(6), 507-512 (2009).
167. Steen RG, Hankins GM, Xiong X et al. Prospective brain imaging evaluation of children with sickle cell trait: initial observations. Radiology 228(1), 208-215 (2003).